Search | Clinical Trials Finder

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Conditions: Hepatitis C
Interventions: SOF, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Hepatitis A
Interventions: hepatitis A vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 6 Months to 25 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Anchorage, Alaska

Conditions: Uveal Melanoma, Liver Metastases
Interventions: CVA21, Ipilimumab; Biological
Lead sponsor: Viralytics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami Beach, Florida • Boston, Massachusetts

Conditions: Poliomyelitis
Interventions: Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Post-Poliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years to 120 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York

Conditions: Healthy, Neuromuscular Disease, Postpoliomyelitis Syndrome
Interventions: Electromyography; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Torrance, California

Conditions: QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions: artus Influenza A/B RT-PCR Test; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more

Conditions: Spinal Cord Injuries, Poliomyelitis, Post-polio Syndrome, Arthritis, Lower Motor Neurone Lesion
Interventions: C-brace, Stance control orthosis; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Haemophilus Infections, Diphtheria, Tetanus, Polio, Pertussis
Interventions: DTaP-IPV/Hib; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Up to 59 Months
Enrollment: 20,830 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 59
States / cities: Albany, California • Martinez, California • San Francisco, California + 56 more

Conditions: Poliomyelitis
Interventions: Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more

Conditions: Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 84 Days
Enrollment: 1,941 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 26
States / cities: Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Cerebrovascular Accident, Post-polio Syndrome, Spinal Cord Injuries, Multiple Sclerosis, Muscular Dystrophy, Paralysis
Interventions: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH); Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis A
Interventions: Havrix™, Infanrix™, ActHIB™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 22
States / cities: Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
Interventions: Stool and Blood Specimen Collection, Follow-up Medical Record Review; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Enterovirus Infection
Interventions: Placebo, Pleconaril; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 15 Days
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
Interventions: Sucralfate, Placebo, Acetaminophen, Ibuprofen; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Months to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

Study of Mental Fatigue in Polio Survivors

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Electromyography to Diagnose Neuromuscular Disorders

Pilot Study Freeze and Transport Immune Cells

Collection and Testing of Respiratory Samples

Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Nomad P-KAFO Study

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

Pleconaril Enteroviral Sepsis Syndrome

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome